SinoMab BioScience unveils 2026 AGM agenda: board changes, 10% share buy-back mandate and 20% issuance limit

Bulletin Express
Apr 27

28 April 2026 – SinoMab BioScience Limited (SinoMab Bio-B, 03681) has dispatched a circular convening its 2026 Annual General Meeting for 12 June 2026, 10:00 a.m., at Fairmont House, Central, Hong Kong.

Key proposals to be put to shareholders are as follows:

1. Board composition • Re-election of four retiring directors: independent non-executives Dr Chi Ming Lee, Ms Chi Sau Giselle Lee and Mr Nan Shen, plus non-executive Dr Jianmin Zhang. • Election of Ms Lei Xue as non-executive director upon nomination by shareholder group Apricot Entities (aggregate holding >5%). If approved, her three-year term will start on the AGM date; she will not receive director’s fees. • All independent non-executive directors have been assessed as meeting Hong Kong Listing Rules’ independence criteria.

2. Share repurchase mandate • Directors seek renewal of authority to repurchase up to 10% of issued shares (excluding any treasury shares), equal to 138.66 million shares based on the current issued share capital of 1.39 billion shares. • The board states it has no immediate plan to exercise the mandate. Repurchases will be funded from legally available resources and conducted within Listing Rule limits. • Post-buy-back, the largest shareholder, Hainan Haiyao Co., Ltd. (11.46% stake), would hold approximately 12.73% if the mandate were exercised in full—below the 30% threshold that would trigger a mandatory general offer under the Takeovers Code.

3. General issuance mandate • Directors request authority to issue, allot or transfer up to 20% of issued shares (excluding treasury shares), representing 277.33 million shares, with an additional “extension” allowing the aggregate number to be increased by shares repurchased under the above mandate. • The company currently has no definitive plan to issue new shares.

4. Other matters • Re-appointment of Ernst & Young as external auditor and authorisation for the board to fix its remuneration. • Shareholders recorded as at 8 June 2026 will be eligible to attend and vote; the register closes 9–12 June 2026. • Proxy forms must be lodged by 10 June 2026, 10:00 a.m.

No refreshments or corporate souvenirs will be provided at the AGM. A poll will be demanded for all resolutions in accordance with the Listing Rules, with results released via the Hong Kong Stock Exchange and the company’s website.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10